-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seclidemstat Mesylate in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seclidemstat Mesylate in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seclidemstat Mesylate in Myelodysplastic Syndrome Drug Details: Seclidemstat (SP-2577) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seclidemstat Mesylate in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seclidemstat Mesylate in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seclidemstat Mesylate in Chronic Myelomonocytic Leukemia (CMML) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Colorectal Cancer Drug Details: XmAb-717 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seclidemstat Mesylate in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seclidemstat Mesylate in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seclidemstat Mesylate in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seclidemstat Mesylate in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seclidemstat Mesylate in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seclidemstat Mesylate in Ewing Sarcoma Drug Details: Seclidemstat (SP-2577) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temuterkib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temuterkib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Temuterkib in Non-Small Cell Lung Cancer Drug Details: LY-3214996 is...
-
Product Insights
NewEwing Sarcoma – Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
NewChronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024
Empower your strategies with our Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic Myelomonocytic Leukemia (CMML) is a type of rare blood cancer that combines features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It primarily affects the bone marrow and blood cells, resulting in the overproduction of abnormal monocytes (a type of white blood cell) and other blood cells. CMML is characterized by an increased number of monocytes in the...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewMarginal Zone B-cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...